SEER Inquiry System - Home

Welcome to the SEER Inquiry System (SINQ). SINQ is a collection of questions that cancer registrars have had while coding cancer cases. Click Search to look for specific questions or to select questions for a Report.

Recent Questions
<< First    < Prev 10    11 to 20 of 1971    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

MP/H Rules/Histology--Lung:  What is the histology code for lung cancer case identified pathologically from a metastatic site that differs from the histology stated by the physician?  See Discussion.

Final Jun 09 2017

Histology--Heme & Lymphoid Neoplasms: How should histology be coded for final bone marrow diagnosis of myelodysplastic syndrome with excess blasts?  See Discussion.

Final Jun 05 2017

Primary site--Other and Unspecified Urinary Organs:  What is the topography code for a Skene's gland adenocarcinoma?

Final May 23 2017

Grade--Prostate: How are the prostate-related fields completed when documentation in pathology reports only includes one of the new grade groups? See Discussion.

Final Aug 10 2017

MP/H Rules/Histology: What is the histology code of serous tubal intraepithelial (in situ) carcinoma (STIC), bilateral fallopian tubes?

Final May 22 2017

Surgery codes, NOS/Reconstruction--Breast: Would you code a unilateral breast simple mastectomy with tissue expanders and AlloDerm or an acellular dermal matrix as Code 45, Reconstruction with Implant, or Code 46, Reconstruction with Combined Tissue and Implant? See Discussion.

Final May 22 2017

Grade--Appendix:   What is the code and term to use for the grade/differentiation field for well differentiated, Grade 2 neuroendocrine tumor (NET)?  See Discussion.

Final May 04 2017

MP/H Rules/Multiple primaries--Penis: How many primaries should be reported for a diagnosis of invasive squamous cell carcinoma (SCC) of the penis in 6/2011, treated with excision and fulguration followed by 10/2014 penile lesion found to be SCC with basaloid features focally highly suspicious for invasion? Clinically, the 2014 tumor is stated to be in situ and recurrent penile cancer and follow-up in 2/2015 indicates there was no evidence of tumor following treatment. Subsequently, in 3/2016 the patient has another penile lesion biopsy showing SCC in situ suspicious for invasion, clinically stated to be recurrent. See Discussion.

Final May 03 2017

Surgery Primary Site--Melanoma: How should Surgery of Primary Site be coded for a melanoma diagnosed on punch or shave biopsy followed by a wide excision that shows no residual disease and the gross wide excision specimen size showing no residual is greater than 1 cm in all dimensions (length, width and depth)?  See Discussion.

Final Apr 26 2017

Reportability--Bone: Are giant cell tumors (GCT) of the bone that metastasize to the lung reportable?  See Discussion.

Final Apr 24 2017
< Prev 10    Next 10 >